Blake Byers

Extracted Attributes

• Mission

  Extend human healthspan by 20 years through age reversal of immune, metabolic, and vascular systems

• Education

  PhD and MS in Bioengineering from Stanford University; BS in Biomedical Engineering and BS in Economics from Duke University

• Former Role

  General Partner at GV (Google Ventures) for 10 years

• Current Role

  Co-founder of New Limit

• Scientific Focus

  Partial epigenetic reprogramming, induced pluripotent stem cells, and optogenetically controlled neuron transplants

• Investment Success

  10 IPOs including Forty Seven, Arcus, Denali, and Grail

• Scientific Concept: Cellular Switches

  Field: Gene Therapy; Application: Precise control of Yamanaka factors; Limitation: Essential to prevent cancer risks from factor overdose

Timeline

• Began a ten-year tenure as a General Partner at GV (Google Ventures), leading investments in tech and healthcare. (Source: https://www.newlimit.com/team)

  2011-01-01

• Co-founded New Limit with Brian Armstrong and Jacob Kimmel to focus on epigenetic reprogramming and age reversal. (Source: https://www.blakebyers.com/)

  2021-12-01

• Reported investment metrics including 10 IPOs and current focus on AI drug development and longevity. (Source: https://www.blakebyers.com/)

  2024-06-01

Rock-a-bye Baby

"Rock-a-bye baby on the tree top" (sometimes "Hush-a-bye baby on the tree top") is a nursery rhyme and lullaby. It has a Roud Folk Song Index number of 2768.

Web Search Results

• Team | NewLimit

  # Team ## We are an eclectic group of builders, on an ambitious mission. Reach Out Our Leadership Blake Byers Blake builds and invests in companies that move atoms and bits. His recent investments include Neuralink, Vial, Benchling and Freenome. Blake was most recently a General Partner at GV for a decade where he led investments in tech and healthcare companies. Some of his biotech investments include Forty Seven (Nasdaq: FTSV), Arcus (Nasdaq: RCUS), Denali (Nasdaq: DNLI), and Grail (acquired by Illumina). Blake’s incubations include Pact Pharma, a neoantigen T cell therapy company. Blake received a PhD and MS in bioengineering from Stanford University and holds a BS in biomedical engineering and BS in economics from Duke University. Brian Armstrong Co-founder [...] Our Scientific Advisors Alex Marson Scientific Advisor Alex Marson is a professor at UCSF, scientific director of human health at the Innovative Genomics Institute (IGI), and head of the Gladstone-UCSF Institute of Genomic Immunology. Dr. Marson’s research goal is to understand the genetic circuits that control human immune cell function, and his team has pioneered new CRISPR gene editing technologies that offer more precise ways to rewrite DNA programs in human immune cells. Dr. Marson received an AB and an MD from Harvard, a PhD from MIT, and completed his internal medicine residency at Brigham and Women’s Hospital, and an infectious diseases fellowship at UCSF. Benjamin Humphreys Scientific Advisor [...] He's worked across a wide range of biotechs prior to NewLimit such as at Invitae, Calico Labs, and TensixteenBio, where his primary scientific interest was helping improve drug development using novel lenses of biology. Nick has a BA from Colorado College in Neuroscience. In his spare time, he hangs out with his kids, trail runs, reads fantasy books and plays video games ‍ Qiming Yang Senior Research Associate Qiming supports the research team at NewLimit by optimizing sequencing-based assays for cell rejuvenation studies. Prior to NewLimit, Qiming conducted research at the University of California, Berkeley, focusing on the mechanisms underlying chromosome-wide gene regulation during dosage compensation.

• Blake Byers | Build and Invest

  Skip to Content Blake Byers Blake Byers I work on projects that can positively bend the arc of humanity over multiple generations, or are just fun, ideally both. Please reach out, my email is not that hard to find. Twitter @byersblake. #### Investing I am an avowed generalist. I’ve backed early stage companies across personal finance, cancer treatments, quantum computing, blood screening, and enterprise software that have all gone public. My current investments include superintelligence, mathematical reasoning, coding agents, AI drug development, brain computer interfaces and human longevity. [...] #### NewLimit - Give everyone +20 years of healthy life I co-founded NewLimit with Brian Armstrong (CEO and co-founder of Coinbase) and Jacob Kimmel to radically extend human healthspan. Our focus is on partial epigenetic reprogramming as a mechanism for age reversal, starting with the immune, metabolism and vascular systems. Even if we achieved functional age reversal in just one of these systems, the impact on humanity would be immense. But we’re aiming for much more—over the next few years, we plan to expand our efforts to many additional cell types. Already, we’ve found a way to restore youthful function in aged livers. This breakthrough has shifted our perspective on the likelihood of success, and we’re now highly optimistic that aging is a plastic, reversible cell state. [...] We’re looking for team members in functional genomics, computational biology, machine learning, software engineering, and general operations. If you’re passionate about transforming the future of health, come join us! #### Scientific Research I have a PhD in Bioengineering from Stanford but I’ve been running research experiments since high school and continued even into my time at Google Ventures. My published papers cover atherosclerosis, induced pluripotent stem cells, neurodegenerative diseases, and optogenetically controlled human neuron transplants. (1) Investment metrics as of Summer 2024

• Blake Byers - Forbes

  A partner at Google Ventures with a background in biomedical researcher, Blake has invested in companies like Ionic Security, LendUp and Kensho.

• Blake Byers - NewLimit | LinkedIn

  Blake Byers - NewLimit - Stanford University - About - I build and invest in tech and biotech companies. I try to maintain excess capacity.

• Blake Byers (@byersblake) / Posts / X - Twitter

  Cofounder @Newlimit to extend our lifespans. Investor in early stage ambitious founders, 10 IPOs and counting. ex @GVteam. @Stanford bioengineering PhD. Posts.

• Instance Of

  Q5

• Occupation

  researcher